Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ozenoxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 8/20 | 0.45 |
| ▸ | TOP2B | Q02880 | 8/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ozenoxacin SCHEMBL1711829 | 1.00 | TOP2A (0.45) | TOP2ATOP2BKCNH2GSK3BKDM4E | |
| Ozenoxacin SCHEMBL2551660 | 0.99 | TOP2A (0.45) | TOP2ATOP2BKCNH2GSK3BKDM4E | |
| Ozenoxacin SCHEMBL2551666 | 0.99 | TOP2A (0.45) | TOP2ATOP2BKCNH2GSK3BKDM4E | |
| Ozenoxacin SCHEMBL2553345 | 0.99 | TOP2A (0.45) | TOP2ATOP2BKCNH2GSK3BKDM4E | |
| Ozenoxacin SCHEMBL2550848 | 0.99 | TOP2A (0.45) | TOP2ATOP2BKCNH2GSK3BKDM4E | |
| Ozenoxacin SCHEMBL2553340 | 0.99 | TOP2A (0.45) | TOP2ATOP2BKCNH2GSK3BKDM4E | |
| Ozenoxacin SCHEMBL2548603 | 0.98 | TOP2A (0.44) | TOP2ATOP2BKCNH2GSK3BKDM4E | |
| Ozenoxacin SCHEMBL2553347 | 0.96 | TOP2A (0.43) | TOP2ATOP2BKCNH2GSK3BKDM4E | |
| Ozenoxacin SCHEMBL2550845 | 0.96 | TOP2A (0.42) | TOP2ATOP2BKCNH2GSK3BKDM4E | |
| Ozenoxacin SCHEMBL2550846 | 0.96 | TOP2A (0.42) | TOP2ATOP2BKCNH2GSK3BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027255-A1 | Cross-Linked Telechelic Polymer Compositions, Methods of Preparation Thereof, and Methods of Using Same | BETTY YU SKIN TECH ADVISORS LLC (US) | 2026-01-29 | — | — | US | claimed |
| EP-4562097-A2 | CROSS-LINKED TELECHELIC POLYMER COMPOSITIONS, METHODS OF PREPARATION THEREOF, AND METHODS OF USING SAME | Betty Yu Skin Technology Advisors, LLC (US) | 2025-06-04 | — | — | EP | claimed |
| WO-2025080590-A1 | CO-CRYSTALLIZATION OF ACTIVES WITH SACCHARIDE-BASED MOLECULAR FRAMEWORKS | SCIENTIFIC HORIZONS CONSULTING LLC (US) | 2025-04-17 | — | — | WO | claimed |
| WO-2025014745-A2 | COMPOSITE HYDROGEL WOUND DRESSINGS AND METHODS OF USE THEREOF | SAINT JOSEPH'S UNIVERSITY (US) | 2025-01-16 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-4323054-A1 | CATHETERS INCLUDING METALLIC ALLOYS FOR INTRODUCTION OF THERAPEUTIC IONS | Rain Scientific, Inc. (US) | 2024-02-21 | — | — | EP | claimed |
| WO-2024026251-A2 | CROSS-LINKED TELECHELIC POLYMER COMPOSITIONS, METHODS OF PREPARATION THEREOF, AND METHODS OF USING SAME | BETTY YU SKIN TECHNOLOGY ADVISORS, LLC (US) | 2024-02-01 | — | — | WO | claimed |
| US-20230255884-A1 | FINISHED FIBROUS SRUCTURES AND METHODS OF THEIR USE AND PREPARATION | CLEXIO BIOSCIENCES LTD. (IL) | 2023-08-17 | — | — | US | claimed |
| CN-116590394-A | Multiplex amplification primer group, kit and application thereof | 上海奥根诊断技术有限公司 | 2023-08-15 | — | — | CN | claimed |
| CN-113702523-B | Method for measuring N-nitrosodimethylamine content in ozenoxacin | 杭州华东医药集团新药研究院有限公司 | 2023-05-02 | — | — | CN | claimed |
| WO-2023028364-A1 | TARGETED COMPOSITIONS AND USES THEROF | SEPELO THERAPEUTICS, LLC (US) | 2023-03-02 | — | — | WO | claimed |
| CN-112946136-B | Method for determining content of mesylate in ozesamicin | 杭州华东医药集团新药研究院有限公司 | 2023-02-14 | — | — | CN | claimed |
| WO-2022221287-A1 | CATHETERS INCLUDING METALLIC ALLOYS FOR INTRODUCTION OF THERAPEUTIC IONS | RAIN SCIENTIFIC, INC. (US) | 2022-10-20 | — | — | WO | claimed |
| US-20220287990-A1 | TOPICAL JAK INHIBITOR COMBINATION COMPOSITIONS FOR TREATMENT OF INFLAMMATORY SKIN CONDITIONS | SOL-GEL TECHNOLOGIES LTD. (IL) | 2022-09-15 | — | — | US | claimed |
| EP-3989959-A1 | TRANSDERMAL FORMULATIONS | Nexzol Pharma, Inc. (US) | 2022-05-04 | — | — | EP | claimed |
| WO-2026102307-A1 | ACELLULAR BLOOD ALTERNATIVE FOR TRANSFUSION AND ORGAN PERFUSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4734963-A1 | NITRIC OXIDE CONTAINING FOAM FORMULATION FOR TOPICAL MEDICAL USE | Noxy Health Products, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2022029938-A1 | SKIN COMPOSITION | マルホ株式会社 | 2022-02-10 | — | — | WO | disclosed |
| WO-2022030540-A1 | SKIN COMPOSITION | マルホ株式会社 | 2022-02-10 | — | — | WO | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027255-A1 | Cross-Linked Telechelic Polymer Compositions, Methods of Preparation Thereof, and Methods of Using Same | ILK, TELO2, CDH1 | TOP2A 453/4885TOP2B 536/4885KCNH2 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.